Blog
RSS FeedPosted by Michael Wonder on 30 Dec 2020
Junshi Biosciences announces inclusion of toripalimab in the China National Reimbursement Drug List
29 December 2020 - Junshi Biosciences is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug ...
Posted by Michael Wonder on 09 Dec 2020
BeiGene announces the approval in China of Blincyto (blinatumomab) for injection for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
7 December 2020 - BeiGene today announced that the China NMPA has approved Blincyto (blinatumomab) for injection for the treatment of ...
Posted by Michael Wonder on 23 Nov 2020
BeiGene announces the approval of Xgeva (denosumab) in China for the prevention of skeletal-related events in patients with bone metastases from solid tumours and in patients with multiple myeloma
19 November 2020 - BeiGene today announced that the China NMPA has approved Xgeva (denosumab) for the prevention of skeletal-related events ...
Posted by Michael Wonder on 17 Nov 2020
TRACON Pharmaceuticals announces submission for approval of envafolimab (KN035) with the NMPA in China by its corporate partners Alphamab Oncology and 3D Medicine
16 November 2020 - TRACON Pharmaceuticals today announced its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug ...
Posted by Michael Wonder on 10 Nov 2020
EUSA Pharma and BeiGene announce acceptance of a biologics license application for Qarziba (dinutuximab beta) in Chin
9 November 2020 - EUSA Pharma and BeiGene today announced that the biologics license application for Qarziba (dinutuximab beta) was accepted ...
Posted by Michael Wonder on 06 Nov 2020
Xtandi (enzalutamide soft capsules) approved by China NMPA for the treatment of non-metastatic castration-resistant prostate cancer
6 November 2020 - Enzalutamide is now NMPA approved for both non-metastatic and metastatic castration-resistant prostate cancer. ...
Posted by Michael Wonder on 03 Nov 2020
How people in China with rare diseases afford outrageously expensive medicines?
3 November 2020 - Sky high prices are common for patients with rare diseases. ...
Posted by Michael Wonder on 28 Oct 2020
Forxiga cardiovascular outcomes benefit approved in China
28 October 2020 - Update to approval includes DECLARE-TIMI 58 Phase 3 trial that reduced the risk of composite of hospitalisation ...
Posted by Michael Wonder on 21 Oct 2020
Priority review granted to Ascentage Pharma's new drug application for olverembatinib (HQP1351), the first third generation BCR-ABL inhibitor in China
21 October 2020 - Ascentage Pharma today announced that the Center for Drug Evaluation of China's National Medical Products Administration has ...
Posted by Michael Wonder on 12 Oct 2020
Innovent and Lilly jointly announce the NMPA granted marketing approval for Halpryza (rituximab injection) in China
9 October 2020 - Innovent Biologics and Eli Lilly and Company today jointly announce that Halpryza (rituximab injection), a recombinant human/murine ...
Posted by Michael Wonder on 05 Oct 2020
Physician–patient shared decision making, patient satisfaction, and adoption of new health technology in China
2 October 2020 - A cross-sectional study was conducted from July 2016 to October 2016 in Fujian Province and Shanghai, in ...
Posted by Michael Wonder on 28 Sep 2020
International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market
23 September 2020 - This study aims to summarise the international experience of performance-based risk-sharing arrangements and identify the preconditions for ...
Posted by Michael Wonder on 18 Sep 2020
Chi-Med announces second NDA acceptance in China for surufatinib in pancreatic neuroendocrine tumours
17 September 2020 - Hutchison China MediTech today announces that its new drug application for surufatinib for the treatment of ...
Posted by Michael Wonder on 09 Sep 2020
CANbridge Pharmaceuticals receives Chinese marketing approval for Hunterase first enzyme replacement therapy for Hunter syndrome in China
9 September 2020 - CANbridge Pharmaceuticals announced that it received marketing approval from China’s National Medical Products Administration for Hunterase (idursulfase ...
Posted by Michael Wonder on 04 Sep 2020
Innovent announces NMPA granted marketing approval for Sulinno (adalimumab injection) in China
Innovent Biologics today announced that Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by ...